Bing

SEARCH HISTORY

This suggests that analysts have very recently bumped up their estimates for IPXL, giving the stock a Zacks Earnings ESP of 15.00% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP has proven to be very ...
ZACKS · 5/8/2015
According to the complaint the plaintiff alleges on behalf of purchasers of Impax Laboratories Inc (NASDAQ: IPXL) common stock during the period between June 6, 2011 and March 4, 2013, that Impax Laboratories Inc and certain of its officers and directors ...
wallstreetscope.com · 3/17/2015
As previously disclosed, on October 8, 2014, Impax Laboratories (Nasdaq: IPXL) entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Tower Holdings, Inc. (“Tower”), Lineage Therapeutics Inc. (“Lineage”), Roundtable ...
StreetInsider · 12/29/2014
SAN FRANCISCO, Oct. 28, 2014 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is actively investigating alleged misconduct by Impax Laboratories Inc.'s (NASDAQ: IPXL) top executives, including claims that Impax's officers and directors breached their ...
The Business Journal · 10/28/2014
The top of the channel is near $59, so a reasonable profit target is just below this, at $58.50 to $58.75 Impax Laboratories Inc. (IPXL) rallied strongly from below $24 in October to $52.10 in April. That was were the stock peaked and it has been moving in ...
Investopedia · 7/15/2015
During Q1 2015 he increased his stake of IPXL by 279.85% and since then, the stock has risen by 3.5%. IPXL has a market cap of $3.48 billion and an enterprise value of $3.74 billion. The Company is a technology-based, specialty pharmaceutical company ...
Guru Focus · 7/15/2015
The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300) This is a FREE report from Insider Monkey.
INSIDER MONKEY · 4/16/2015
Though recent challenges with its manufacturing facility in Hayward, CA involving an FDA Warning Letter & multiple Form 483 letters have held down the stock price, we believe that IPXL management & the Board of Directors fully understands the negative ...
Benzinga · ByDwight Einhorn · 11/13/2013
Company % Change Impax Laboratories (NASDAQ: IPXL ) (26%) SandRidge Mississippian Trust I (NYSE ... new ones inevitably crop up. Impax's stock lost more than a quarter of its value yesterday after the regulatory agency said for the third time that it ...
The Motley Fool · ByRich Duprey · 3/7/2013
In this article we have analyzed the three stocks in the biopharmaceutical sector that are awaiting FDA approval ... to be catalysts for stock price appreciation. Particularly in the case of Impax (NASDAQ:IPXL), with its upcoming approval for a drug ...
Seeking Alpha · 9/12/2012